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Objectives The first cause of tooth loss in developed countries is periodontitis. Chronic periodontitis is the most common 
form of periodontitis and it is characterized by loss of periodontal attachment, destruction of alveolar bone and 
eventual loss of teeth. Atorvastatin is a statin drug used for the treatment of high cholesterol. Statins can stop the 
inflammatory process by inhibiting the cholesterol pathway. Diclofenac is an NSAID with anti-inflammatory, anti-
pyretic and analgesic effects. Its primary mechanism is through the inhibition of prostaglandins synthesis by the 
inhibition of the cyclooxygenase enzyme (COX). The purpose of this study is to compare the effects of local injected 
and oral intake of Diclofenac and atorvastatin on alveolar bone density measured in HUs with the use of a CT scan in a 
periodontitis-induced model in rats. 
Methods Thirty rats were randomly divided into 6 groups of 5 rats each. Ligatures were placed around the left second 
maxillary molar to induce periodontitis for 10 days. Administration of 12.5 mg/kg of oral atorvastatin (group 1), 0.25 
mg/kg of injectable atorvastatin (group 2), 7.5mg/kg of oral Diclofenac (group 3), 6.25mg/kg of injectable Diclofenac 
(group 4), the oral solvent without medicine as oral control (groups 5), and the injectable solvent without medicine 
as injectable control (group 6). In each group, the right side of maxilla was considered as control group (without 
ligature and drug interaction). At day eleven, the rats were sacrificed and the maxillary bone was separated from the 
soft tissue and fixed in 4% formalin. The prepared samples were then radiologically evaluated to determine the bone 
density with CT in fixed exposure conditions.  
Results There was a statistically significant difference between the alveolar bone density of the oral atorvastatin 
group and the oral Diclofenac (P = 0.006). There was no statistical significant difference in alveolar bone density 
between the injectable atorvastatin and the injectable Diclofenac groups (P=0.228). 
Conclusion Both atorvastatin and Diclofenac have shown better results when assessing bone density in a periodontitis rat 
model  as compared to controls. Additionally, Diclofenac has been shown to be more effective at both oral and injectable 
administrations as compared with atorvastatin in the prevention of loss of bone density in a rat model with periodontitis. 





The first cause of tooth loss in developed countries is 
periodontitis.
1
 Chronic periodontitis is the most common 
form of periodontitis. It is an inflammation of the 
periodontal tissues resulting in loss of periodontal 
attachment, destruction of alveolar bone, periodontal 
pocketing formation, and eventual loss of teeth. Chronic 
periodontitis is a multi-factorial disease initiated by 
microbial plaque. Its extension and severity within each 
individual is influenced by the genetic and environmental 
factors of each subject.
2
 The process of inflammation starts 
from superficial tissues (sulcular and junctional epithelium) 
and spreads to deeper connective tissues.
3
 The initial 
inflammatory response to the dental microbial plaque is 
headed by polymorphonuclear neutronphils (PMNs), 
which will detect the antigens of the microorganisms 
through their surface receptors. The activation of these 
receptors by the pathogen results in their phagocytosis and 
the secretion of pro-inflammatory cytokines such as IL-8, 
IL-6, IL12 and TNF- α, which cause periodontal tissue 
destruction.
4
 In the inflamed gingiva, high levels of the 
tissue- degrading enzymes such as matrix metalloproteinase 
(MMPs) are found. MMPs cause the destruction of the 
extracellular matrix; including collagen, gelatin, and elastin 
which will eventually result in periodontal tissue 
destruction and the loss of alveolar bone.
3
 When the 
inflammatory products reach the bone surface bone 
destruction might start representing in this way the transition 
from gingivitis to periodontitis. The height and density of 
the alveolar bone is regulated by a balance between 
bone forming cells (osteoblasts) and bone-resorbing cells 
(osteoclasts), all affected by the systemic and local 
environment. If the bone resorption surpasses its formation 
rate, there will be a reduction in bone density, a reduction 
of alveolar bone height, or both.
4
 Atorvastatin is a member 
of the drug class known as statins, which had a 
revolutionary impact on the treatment of high cholesterol. 
Statins reduce the production of mevalonate, geranyl  
pyrophosphate, and farnesyl pyrophosphate and the other 
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production in the way of cholesterol creation. Statins can 
stop the process of inflammation by inhibiting the 
cholesterol pathway and by interfering with the function 
of the RAS family of proteins.
5
 Additionally, atorvastatin 
has shown to suppress MMPs.
6
 Statins are also strong 
stimulants of bone morphogenetic protein-2 (BMP-2).
7
 
Diclofenac is an NSAID derived from phenyl-acetic acid 
and has a structure similar to Flurbiprofen. It has anti-
inflammatory, anti-pyretic and analgesic effects. Its primary 
mechanism is through the inhibition of prostaglandin 
synthesis by the inhibition of the cyclooxygenase enzyme 
(COX). This drug is used in the treatment of osteoarthritis 
and rheumatoid arthritis.
8
 Computed-Tomography (CT) 
uses computer- processed combinations of X-ray slices of 
a structure to obtain cross-sectional images. CT scanners 
use the emitted x-ray from the body of a patient to produce 
sectional images. The X-ray taken out of the body of the 
patient is sensed by a detector. The detector measures the 
output x-ray severity of the patient and sends it as digital 
data to a computer for analysis. The computer converts 
this digital data to numerical information that is expressed 
as the number of CT (CT number) or Hounsfield Units 
(HUs). Numerical data is represented in images taken 
from the patient as a gray shade to indicate the different 
tissue densities that in the darkest (radiolucent) case may 
represent the air density and in the clearest (opaque) case 
represents very dense tissues such as bone. Hounsfield 
Unit (HU) scale is a standard para-clinical densitometry 
method that is used to check the density of the body bones, 
including maxilla and mandible. As of today, many studies 
indicate that the use of HU scale is a very useful method to 
evaluate the bone density of maxilla and mandible.
9
 
Numerous laboratory animal species including non-human 
primates, dogs, and rodents have been used to study the 
pathophysiology, the radiographic changes, or the outcomes 
of preventive treatments in periodontitis.
10
 
Several studies showing different results have been 
conducted on the effect of atorvastatin on bone 
formation and bone loss. 
Balli et al. (2014) performed a study in various phases of 
periodontitis on 100 rats, where the effect of topical 
atorvastatin was examined for the first time. They 
concluded that atorvastatin was useful in the treatment of 
periodontal disease.
11
 In another study by Araújo Jr et al. 
(2013) on the anti-inflammatory properties of atorvastatin, 
it was concluded that there was a decrease of the gingival 
inflammation and a decrease in bone resorption.
5
 In a 
study performed by Goes et al. (2010) to assess the 
effect of atorvastatin on bone density with the help of 
digital radiography, high doses of atorvastatin were capable 
of preventing bone loss in a ligature-induced periodontitis 
model.
12
 On the other hand, Chang et al. (2011) found 
that atorvastatin did not affect the bone density even at high 
doses
13
 by DEXA method (The method in which is used x-
ray to measure the bone density). Several studies have also 
been performed to evaluate the effects of Diclofenac and 
bone loss. 
Kurunj Kumarun et al. (2012) showed that the Diclofenac 
sodium even at low concentration diminishes the number 
of osteoclasts hence reducing bone loss.
14
 Additionally; 
Ghalyani et al. (2014) assessed the effect of Diclofenac and 
celecoxib in relation to the osteoclastogenesis during the 
healing period after tooth extraction. Both Diclofenac and 
celecoxib caused a decrease in osteoclast production, 
reducing in this way the bone loss after tooth extraction.
15
 
The cited studies have not examined deeply the topical 
injection and oral effects of Diclofenac and atorvastatin 
on the alveolar bone density in periodontal disease. To our 
knowledge, there is not a study comparing the effects of 
these two drugs together. Moreover, very few studies 
have been performed using HUs to measure the bone 
density despite it is considered the standard method for 
densitometry. 
The aim of this study is to compare the effects of the 
topical injection and oral administration of either 
Diclofenac or atorvastatin in the alveolar bone density in 
areas with ligature–induced periodontal disease assessed in 
HU with the use of CT in rat. 
 
Materials and Methods 
 
Based on previous studies 
5, 11, 12, 14, 15
 and by the use of 
SPSS, 30 male Sprague-Dawley rats weighting of 180 to 
200g and with the age of 8 to 12 weeks were used. 
After adequate anesthesia with sub cutaneous injection of 
animal ketamine hydrochloride combination as 10% at a 
dose of 70 mg/ kg and 2% xylazine at a dose of 10 mg/ kg, 
periodontal disease was induced by placing a ligature 
thread (3-0 ETHIBOND EXCEL polyster green coated 
braided non absorbable) on the gingival sulcus around the 
left second maxillary molar and tied in the palatal area.
16
 
In the study, 30 rats were randomly divided into 6 groups 
of 5 rats each. The ligature thread was tied around the 
left second maxillary molar for 10 days to induce 
periodontitis. The animals were daily administered with 
12.5 mg / kg of oral atorvastatin by Gavage method (group 
1), they were injected 0.25 mg / kg of injectable atorvastatin 
in the alveolar crest of the second left maxillary molar 
(group 2),  7.5mg/ kg of oral Diclofenac by Gavage method 
was administered (group 3), injectable Diclofenac as 6 
.25mg / kg was injected in the alveolar crest of the 
second left maxillary teeth (group4), administration of 
solvent without drug as xsoral control (group 5) and the 
injectable solvent without drug as injectable control 
(group 6). In each group, the right side of maxilla was 
considered as control group (without ligature and drug 
interaction). The selection of drug doses have been done 
based on previous studies that have shown to be effective in 
reducing inflammation in rats.
17
 
The animals in all the groups were kept in a standard 
condition (12 hours of day and 12 hours of night and at 
a temperature of 22 ° C with access to food and water).
18
 
The sagittal profile of the prepared samples was 
radiologically evaluated to determine the bone density by 
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Hounsfield Unit technique with CT in the exposure 
conditions of 1 mAs and 120 kvp. In the images that were 
taken from samples, gray shades indicate the different tissue 
densities (in the darkest case it may represent the air 
density and in the clearest case it represents very dense 
tissues such as bone). Then the bone density of the studied 
area (alveolar bone of second maxillary molar) was 
measured by using the existing software on CT scan 
device (GE: Milawaukee, USA) as numerical information 
that is expressed as CT values or HUs. These CT values 
or HUs were compared between the samples with 
periodontal defects without drug administration versus the 
samples having the periodontal defects with drug 
administration both as topical and as oral injection. That is 
how the considered bone tissues include the lower 
Hounsfield unit or in other words the lower number of CT, 
tissue density is lower and the higher Hounsfield unit or 
CT number is, the greater tissue density is. 
Data analysis was performed by SPSS versoin 18. Data 
was described by using the mean (±Standard deviation). 
Analysis of one-way variance (One-Way ANOVA) was 
used as well as Tukey HSD test to compare the bone 
density at control sides.  Also, the analysis of covariance 
(ANCOVA) was used to compare the amounts of bone 
density  between  the  ligature- induced periodontitis  
groups when their  values  of  bone  density  at  control  
sides were considered as the independent variable 





No statistical significant difference was found between 
the bone density at control sides (p=0.071) (Table 1). 
Table 1- Comparison of mean bone density at  the 
control sides between the groups 






GC /ORAL 1450.20±253.09AB 
GC/INJECT 1161.40±241.40AB 
One- way ANOVA F TEST 
Mean values with at least a common letter in superscript (AB) were 
not statistically different (Post-Hoc Turkey HSD test) 
The mean difference is significant at the 0.05 level. 
 
There was statistically significant difference between mean 
bone density at intervention sides of the groups when their 
values of control sides were controlled. (P=0.383) 
There was not statistical significant difference between the 
alveolar bone density of the oral and injectable 
atorvastatin groups. (P=0.615) 
There was a statistically significant difference between the 
alveolar bone density of the oral atorvastatin group as 
compared with the oral control group (P=0.31) (Table 2). 
Although the value of the oral Diclofenac group was 
1,011.51 HU, and the value of the oral control group was 
909.42 HU, this difference was not statistically significant 
(P=0.505) (Table 2). 
Also no statistically significant changes in the alveolar 
bone density were found when comparing the injectable 
control group with the injectable Diclofenac group 
(P=0.075) (Table 2). The mean alveolar bone density of 
the oral Diclofenac group was 797.91HU which was 
higher than the mean alveolar bone density of the 
injectable control group 759.76 HU. 
There was a statistically significant difference between the 
alveolar bone density of the oral atorvastatin group and the 
oral Diclofenac. (P=0.006) 
The difference between the alveolar bone density of the 
injectable atorvastatin group and the injectable Diclofenac 
did not reach statistical significance (P=0.228) (Table 2). 
The mean alveolar bone density of the injectable 
Diclofenac group had a value of 797.91HU which was 
more than the value of the injectable atorvastatin which 
was 601.59HU. 
There was statistically significant difference between the 
alveolar bone density of the injectable atorvastatin and the 
oral Diclofenac (P=0.012) (Table 2). 
Table 2- Comparison of mean bone density at the ligature-
induced periodontits sides between groups 





Oral Atorvastatin 458.80±247.11 515.19A 
0.038 
Injected Atorvastatin 656.00±76.94 601.59A 
Oral Diclofenac 1043.00±319.48 1011.51B 
Injected Diclofenac 779.40±250.56 797.91AB 
Oral Control group 968.80±322.46 909.428B 
Injected Control group 686.400±103.74 756.76AB 
ANCOVA F TEST 
Mean values with at least a common letter in superscript (AB )  were not 
statistically different  (post – hoc sidac test) 




Periodontitis is related to several inflammatory mediators, 
which contribute not only to bone homeostasis, but also to 
tissue destruction. Considering that local bone loss is an 
immunoinflammatory exacerbated reaction and localized 
osteoclastogenesis combination, ligature-induced alveolar 
bone loss occurs due to abnormal activation of host 
immunological system with consequent uncontrolled 
inflammatory response.
16
 In order to evaluate periodontal 
condition several assays have used conventional 
radiographic images, due to the obvious bone alterations 
seen However, when bone anabolic events are still subtle, 
conventional biochemical and radiographic markers are not 
always sensitive enough to reveal such changes. This way, 
images of Hounsfield units present an addition advantage, 
as they demonstrate capacity to reveal larger number of 
early sites with bone loss.
19
 In this study, Ligatures were 
placed around the left second maxillary molar to induce 
periodontitis for 10 days. Administration of 12.5 mg/kg of 
oral atorvastatin (group 1), 0.25 mg/kg of injectable 
atorvastatin (group 2), 7.5mg/kg of oral Diclofenac (group 
3), 6.25mg/kg of injectable Diclofenac (group 4), the oral 
solvent without medicine as oral control (groups 5), and 
the injectable solvent without medicine as injectable 
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control (group 6). In each group, the right side of maxilla 
was considered as control group a t eleven day, the rats 
were sacrificed and the maxillary bone was separated from 
the soft tissue. The prepared samples were then 
radiological evaluated to determine the bone density with 
CT. The results of the present study show that both 
Diclofenac and atorvastatin are effective in preventing bone 
density loss. Nevertheless, Diclofenac is more effective 
both orally and injectable as compared with atorvastatin in 
the prevention of bone density loss in rats with ligature-
induced periodontitis. 
Numerous studies have been performed on the effects of 
atorvastatin on bone formation and its resorption with 
different results. 
Chang et al. (2011) performed a study by DEXA method 
they stated that atorvastatin did not have any effect on the 
bone density even at high doses.
14
 The results of this study 
have been consistent with the present study results, 
making in that way questionable the effectiveness of 
atorvastatin on the bone density. 
Other studies have concluded that periodontal disease 
causes an increase in lipid peroxidation.
19
 In a study 
conducted by de Araújo et al. (2013) it was shown that oral 
atorvastatin at doses of 10 mg/kg in ligature-induced 
periodontitis model in rats reduced the lipid peroxidation, 
which ultimately led to a reduction on inflammation and 
bone loss.
5
 In another study performed by Bali et al. 
(2014) on 100 rats, it was compared for the first time the 
effect of local versus systemic administration of 
atorvastatin. They reported a positive effect of both 
administration paths on the periodontium by 
histomorphometry and imonohistochemistry tests.
11
 
Goes et al. (2010) performed a study to assess the effect of 
atorvastatin on bone density with the help of digital 
radiography. They concluded that atorvastatin can 
prevent bone resorption by reducing pro- inflammatory 
cytokines such as I L-8, IL-6, IL-12 and TNF-α.
12
 
The results of the aforementioned studies show different 
findings as compared to the present study. The reasons for 
this differences could be related to the use of oral and 
injectable drug doses, as well as the examination method 
used to determine the bone changes in the present 
study. The doses used of atorvastatin have been higher 
than the ones used in the previous studies. The drug dose 
selection is based on previous studies, showing an 
effectiveness in reduction of inflammation.
17
  
This study also differs in the examination method of the 
bone changes. HU scale which is considered to be the 
standard densitometry method of assessing bone density 
was used in this study, which differs from the previous 
studies. 
HU scale assessment is one of the most accurate para-
clinical methods to evaluate the bone density, and it is used 
in numerous studies. 
Turkyilmaz et al. (2007) performed a study to assess the 
bone density in areas scheduled for dental implants. They 
analyzed their results with a standardized HU scale.
20
 In 
another study conducted by Aksoy et al. (2009), it was 
stated that assessment with HUs is a suitable method to 
determine the bone quality to predict the implant stability.
21
 
Diclofenac is a NSAID which has been suggested in 
several studies to inhibit the bone resorption 
Additionally, evidence has concluded that the use of 




Kurunj Kumarun et al. (2012) showed that Diclofenac 
sodium even at low concentration levels diminishes the 
number of osteoclasts probably by inhibiting the secretion 
of prostaglandins and in that way reducing the orthodontic 
tooth movement as a result of reducing the bone loss.
14
 
Ghalyani et al. (2014) performed a study to assess the effect 
of Diclofenac and celecoxib on the osteoclastogenesis during 
the healing process of the alveolar bone after tooth 
extraction. They concluded that both Diclofenac and 
celecoxib reduced osteoclast production by decreasing 
expressions ratio of RANKL / OPG genes, and resulting 
in the decrease of the bone loss after tooth extraction.
16
 
In the present study, oral Diclofenac has been more 
effective in preventing bone density reduction as 
compared to the injectable Diclofenac in the ligature-
induced periodontitis rat model. One of the reasons that 
oral Diclofenac performed better than its injectable form 
might be related to the trauma caused after the drug 
injection in the periodontal tissues. This might exacerbate 
the inflammation and destruction of the periodontium. 
In this study, Diclofenac was more effective administered 
both orally or as an injection when compared to atorvastatin 
in the prevention of bone density loss in periodontal disease. 
The role of inflammation in the development of chronic 
periodontitis has been recognized.
3 
Diclofenac is a potent 
anti-inflammatory drug due to its relation with the 
cyclooxygenase pathway and blocking both COX1 and 
COX2 metabolites.
8
 As a result, it can be more effective in 
minimizing bone density reduction. The balance between 
the numbers of osteoblasts is the main determinant for bone 
density. Diclofenac can reduce the production of osteoclasts 
by decreasing expressions ratio of RANKL / OPG genes. 





Finally, according to the present study, Diclofenac has been 
shown to be more effective at both oral and injectable 
administrations as compared with atorvastatin in the 
prevention of loss of bone density in a rat model with 
periodontitis. Hence, according to the present study that for 
the first time has been conducted using Hounsfield units 
(HU) that is the method of standard Para-clinic 
densitometry that is performable in all the bones in the 
body as well as for the first time, it has been compared the 
effects of these drugs on the bone density with each other, it 
is required more studies in this field., 
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